Article Versions Notes

Cefalì M, Epistolio S, Ramelli G, Mangan D, Molinari F, Martin V, Freguia S, Mazzucchelli L, Froesch P, Frattini M, et al. Correlation of KRAS G12C Mutation and High PD-L1 Expression with Clinical Outcome in NSCLC Patients Treated with Anti-PD1 Immunotherapy. Journal of Clinical Medicine. 2022; 11(6):1627. https://doi.org/10.3390/jcm11061627

Cefalì, Marco, Samantha Epistolio, Giulia Ramelli, Dylan Mangan, Francesca Molinari, Vittoria Martin, Stefania Freguia, Luca Mazzucchelli, Patrizia Froesch, Milo Frattini, and et al. 2022. "Correlation of KRAS G12C Mutation and High PD-L1 Expression with Clinical Outcome in NSCLC Patients Treated with Anti-PD1 Immunotherapy" Journal of Clinical Medicine 11, no. 6: 1627. https://doi.org/10.3390/jcm11061627

Cefalì, M., Epistolio, S., Ramelli, G., Mangan, D., Molinari, F., Martin, V., Freguia, S., Mazzucchelli, L., Froesch, P., Frattini, M., & Wannesson, L. (2022). Correlation of KRAS G12C Mutation and High PD-L1 Expression with Clinical Outcome in NSCLC Patients Treated with Anti-PD1 Immunotherapy. Journal of Clinical Medicine, 11(6), 1627. https://doi.org/10.3390/jcm11061627